Lotus eye hospital And Institute Limited has been penalized by both major Indian stock exchanges for regulatory non-compliance. The healthcare company disclosed that BSE Limited and National Stock Exchange of India Limited have each imposed fines of Rs 2,17,120, inclusive of GST, for violations under SEBI listing regulations.

Regulatory Violation Details

The penalty stems from non-compliance with Regulation 17(1A) of the SEBI (LODR) Regulations, 2015. The company received official communication regarding this action through email and letter dated February 27, 2026.

Remedial Actions Taken

Lotus Eye Hospital And Institute Limited has taken steps to address the compliance issue. The company rectified the non-compliance through shareholder approval obtained via postal ballot, with resolutions deemed to have been passed on January 17, 2026.

The company's board of directors acknowledged the non-compliance comments at their meeting held on February 11, 2026. Subsequently, the board's observations were communicated to both stock exchanges on February 12, 2026.

Financial Impact Assessment

According to the company's disclosure, the regulatory penalty will not have any material impact on its financial operations. The healthcare institution has also clarified that stock exchanges had previously levied fines up to the quarter ended September 30, 2025, which the company has duly paid.

Corporate Background

The present penalty specifically pertains to the quarter ended December 31, 2025. The company operates multiple healthcare facilities across Tamil Nadu and Kerala, with locations in Coimbatore, Salem, Tirupur, Mettupalayam, Kochi, and Karur, specializing in eye care services.

Lotus Eye Hospital and Institute Limited has witnessed a significant inter-promoter share transfer, with Sangeetha Sundaramoorthy acquiring additional equity stake from Kavetha Sundaramoorthy under SEBI takeover regulation exemptions.

Transaction Details

The acquisition involved 14,28,571 shares purchased at Rs.70 per share through a share purchase agreement executed on June 2, 2025. The transaction was completed on February 27, 2026, representing 6.8693% of the company's diluted share capital.

Regulatory Compliance

The transaction was executed under Regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which provides exemption from making an open offer for inter-promoter transfers. Sangeetha Sundaramoorthy filed the required disclosure with BSE and NSE on January 27, 2026, adhering to the timeline specified under Regulation 10(5).

Shareholding Changes

The inter-promoter transfer resulted in significant changes to the ownership structure between the two promoters:

Market Listing

Lotus Eye Hospital and Institute Limited shares are listed on both BSE and NSE. The company operates in the healthcare sector, specifically focusing on eye care services and related medical treatments.

Regulatory Framework

The transaction falls under the exemption category that allows promoters to transfer shares among themselves without triggering mandatory open offer requirements, provided proper disclosures are made to stock exchanges within stipulated timelines.